Adenoviral vector

1. An adenoviral vector comprising:

genome of an adenovirus other than AdHu5 and AdY25,

wherein the genome of the adenovirus has been modified such that the vector lacks native E4 locus of the adenovirus and comprises heterologous E4Orf1, E4Orf2 and E4Orf3 coding regions from AdY25, and heterologous E4Orf4, E4Orf6 and E4Orf6/7 coding regions from AdHu5 in the E4 locus of the adenovirus.

2. The adenoviral vector of claim 1 , wherein said adenovirus is C68.

3. The adenoviral vector of claim 1 , wherein said adenoviral vector lacks a functional E1 locus or E3 locus.

4. The adenoviral vector of claim 1 , wherein said adenoviral vector comprises one or more capsid proteins selected from the group consisting of:

(a) a hexon protein encoded by coding sequence corresponding to nucleotides 18315 to 21116 of SEQ ID NO. 1;

(b) a penton protein encoded by coding sequence corresponding to nucleotides 13884 to 15488 of SEQ ID NO. 1; and

(c) a fiber protein encoded by coding sequence corresponding to nucleotides 32134 to 33411 of SEQ ID NO. 1.

5. The adenoviral vector of claim 1 , further comprising an exogenous nucleotide sequence of interest that encodes a protein or polypeptide.

6. The adenoviral vector of claim 5 , wherein said protein or polypeptide is selected from the group comprising an antigen, a molecular adjuvant, an immunostimulatory protein or a recombinase.

7. The adenoviral vector of claim 6 , wherein the antigen is a pathogen-derived antigen.

8. The adenoviral vector of claim 7 , wherein the pathogen is selected from the group consisting of M. tuberculosis, Plasmodium spp, influenza virus, HIV, Hepatitis C virus, Cytomegalovirus, Human papilloma virus, rabies virus, measles virus, mumps, rubella, zika virus, leishmania parasites, Mycobacterium spp, and Mycobacterium avium subspecies paratuberculosis (MAP).

9. The adenoviral vector of claim 8 , wherein the antigen is rabies virus glycoprotein.

10. The adenoviral vector of claim 5 , wherein said exogenous nucleotide sequence of interest is a miRNA or immunostimulatory RNA sequence.

11. An immunogenic composition comprising the adenovirus vector according to claim 1 and optionally one or more additional active ingredients, a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

12. A polynucleotide sequence encoding the adenoviral vector of claim 1 .

13. A host cell transduced with the adenoviral vector of claim 1 .

14. A method of producing the adenoviral vector of claim 1 , comprising the step of incorporating a polynucleotide sequence encoding said adenoviral vector into a Bacterial Artificial Chromosome (BAC) to produce an Ad-BAC vector.

15. A Bacterial Artificial Chromosome (BAC) clone comprising the polynucleotide sequence of claim 12 .

16. A packaging cell line producing the viral vector of claim 1 .

17. The packaging cell line of claim 16 , wherein said cell comprises complement of any genes functionally deleted in the viral vector of claim 1 .

18. A kit comprising: (i) one of an adenoviral vector according to claim 1 or an immunogenic composition comprising the adenoviral vector according to claim 1 , and (ii) instructions for use.

19. A method of treating or preventing a disease comprising administering the immunogenic composition according to claim 11 to a subject in need thereof.

20. The method of claim 19 , wherein the disease is selected from the group comprising tuberculosis, Johne's disease, Crohn's disease, malaria, influenza, HIV/AIDS, Hepatitis C virus infection, Cytomegalovirus infection, Human papilloma virus infection, adenoviral infection, leishmaniasis, Streptococcus spp infection, Staphylococcus spp infection, Meningococcus spp infection, foot and mouth disease, chikungunya virus infection, Zika virus infection, rabies, Crimean Congo haemorrhagic fever, Ebola virus infection, Marburg, Lassa fever, MERS and SARS coronavirus disease, and Nipah and Rift Valley fever.

21. The method of claim 19 , wherein the method comprises delivering a transgene into a host cell of the subject.